Cision PR Newswire
FULC Investors Have Opportunity to Lead Fulcrum Therapeutics, Inc. Securities Fraud Lawsuit
News provided byLaw Offices of Howard G. Smith
May 26, 2023, 9:00 AM ET
BENSALEM, Pa., May 26, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC).
Class Period: March 3, 2022 – March 8, 2023
Lead Plaintiff Deadline: June 27, 2023
Investors suffering losses on their Fulcrum investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to firstname.lastname@example.org.
On February 24, 2023, Fulcrum announced that the U.S. Food and Drug Administration (FDA) verbally informed the company that it has issued a full clinical hold regarding the Investigational New Drug application for its sickle-cell disease treatment, FTX-6058, due to previously reported preclinical data.
On this news, Fulcrum's stock price fell $7.23 per share, or 56%, to close at $5.66 per share on February 24, 2023, thereby injuring investors.
Then, on March 9, 2023, before the market opened, Fulcrum released its fourth quarter and full year 2022 financial results, revealing that the previously reported preclinical data referenced by the FDA involved "non-clinical and clinical evidence of hematological malignancies observed with other inhibitors of polycomb repressive complex 2 (PRC2)," and noted that "the profile of hematological malignancies observed in the non-clinical studies of FTX-6058 is similar to that observed with other inhibitors of PRC2, and that hematological malignancies have been reported clinically with other PRC2 inhibitors." The FDA requested that Fulcrum "further define the population where the potential benefit of continued treatment with FTX-6058 outweighs potential risk."
On this news, Fulcrum's stock price fell $1.44, or 23%, to close at $4.82 per share on March 9, 2023, thereby injuring investors further.
The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) the preclinical data submitted in support of FTX-6058 showed safety concerns regarding potential hematological malignancies; (2) the foregoing safety concerns increased the likelihood that the FDA would place a clinical hold on preclinical studies of FTX-6058; (3) accordingly, the Company had overstated FTX-6058's clinical and/or commercial prospects; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to email@example.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE Law Offices of Howard G. Smith
NOTE: This content is not written by or endorsed by "WTTV", its advertisers, or Nexstar Media Inc.